News Sentiment

ELVN sentiment intelligence

Enliven Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 51.09 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+2.5% over one week, +10.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Enliven Therapeutics stock hits 52-week high at 52.47 USD

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 2.5% Price confirming higher
Trend fit Trend active 10.8% over four weeks
Fair value 126.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 34
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 12
Investing.com 6
PR Newswire 6
TradingView 4
MT Newswires 3
Investing.com Canada 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 11
Analyst action 7
Deals and strategy 4

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Investing.com Direct company coverage

Enliven Therapeutics stock hits 52-week high at 52.47 USD

Enliven Therapeutics (ELVN) has reached a new 52-week high of $52.47, reflecting a significant year-to-date return of 236% and a 143.2% increase over the past year. Despite this surge, InvestingPro data suggests the stock appears overvalued relative to its Fair Value. The company

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 17:11
Source
Investing.com
Investing.com Canada Direct company coverage

H.C. Wainwright raises Enliven Therapeutics price target on trial data By Investing.com

H.C. Wainwright increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $65 from $56, maintaining a Buy rating, following positive Phase 1 trial data for ELVN-001 in chronic myelogenous leukemia. The stock has seen a significant year-to-date surge, and analysts hold

Tone
Positive 94/100
Event
Analyst action
Published
09 Jul 2026 11:41
Source
Investing.com Canada
Simply Wall Street Direct company coverage

Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich?

Enliven Therapeutics (ELVN) was recently removed from several Russell indexes, yet its share price has seen significant gains. Despite trading below the average analyst target, the company's Price-to-Book ratio of 7.8x is well above the industry average, suggesting a rich valuati

Tone
Negative 39/100
Event
Analyst action
Published
09 Jul 2026 01:40
Source
Simply Wall Street
Stock Titan Direct company coverage

Enliven Therapeutics (ELVN) director sells 10,000 shares under 10b5-1 plan

Enliven Therapeutics director Lori Anne Kunkel sold 10,000 shares of common stock on July 6, 2026, through two open-market transactions at weighted average prices of $50.8442 and $49.9834 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan establis

Tone
Negative 29/100
Event
Market update
Published
08 Jul 2026 21:40
Source
Stock Titan
Stock Traders Daily Direct company coverage

How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing

This article analyzes Enliven Therapeutics Inc. (NASDAQ: ELVN) using AI models to determine its impact on rotational strategy timing. It highlights a near-term neutral sentiment amidst mid and long-term strength, identifying a mid-channel oscillation pattern and a significant ris

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 02:22
Source
Stock Traders Daily
Stock Titan Direct company coverage

If You Invested $1,000 in Enliven Therapeutics Inc (ELVN)

This article examines the historical performance of investing $1,000 in Enliven Therapeutics Inc (ELVN) over various timeframes, detailing the significant returns an investor would have seen. It also provides an in-depth company profile, outlining Enliven Therapeutics' focus on p

Tone
Positive 77/100
Event
Market update
Published
04 Jul 2026 08:09
Source
Stock Titan
GuruFocus Direct company coverage

ELVN Maintained by Stifel -- Price Target Raised to $80

Stifel maintained a "Buy" rating for Enliven Therapeutics (ELVN) and raised its price target from $60 to $80 on July 1, 2026, indicating optimism about the company's future. Despite this positive analyst outlook, ELVN has a low GF Score™ of 28/100, primarily due to weak profitabi

Tone
Positive 68/100
Event
Analyst action
Published
01 Jul 2026 14:40
Source
GuruFocus
Investing.com Nigeria Direct company coverage

Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com

Jones Trading has increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $70 from $45, reiterating a Buy rating. This adjustment follows a positive Phase I trial update for ELVN-001 in chronic myeloid leukemia (CML) and the company's decision to pursue first-line an

Tone
Positive 82/100
Event
Analyst action
Published
30 Jun 2026 00:11
Source
Investing.com Nigeria
Investing.com Direct company coverage

Jones Trading raises Enliven Therapeutics price target on CML trials

Jones Trading increased its price target for Enliven Therapeutics (NASDAQ:ELVN) from $45 to $70, while maintaining a Buy rating, based on a positive Phase I update for its CML trials. The biotech company's stock has surged 214% in six months, and Jones Trading revised its model t

Tone
Positive 73/100
Event
Analyst action
Published
29 Jun 2026 23:10
Source
Investing.com
Market source Direct company coverage

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

OrbiMed Advisors, a significant shareholder in Enliven Therapeutics (NASDAQ: ELVN), recently sold 860,123 shares worth approximately $39 million. This sale represents an 11.60% reduction in their indirect holdings but still leaves OrbiMed as a major shareholder with over 6.5 mill

Tone
Positive 67/100
Event
Market update
Published
27 Jun 2026 12:23
Source
Market source
TradingView Direct company coverage

Enliven Therapeutics, Inc. Actuals & Estimates (NASDAQ:ELVN)

This article provides an overview of Enliven Therapeutics, Inc. (NASDAQ: ELVN) stock performance, financial data, and analyst forecasts. It includes current stock price, historical highs and lows, market capitalization, earnings per share, revenue, and upcoming earnings report da

Tone
Positive 67/100
Event
Earnings
Published
26 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

ELVN Forecast — Price Target — Prediction for 2027

This article provides a forecast and various financial metrics for Enliven Therapeutics, Inc. (ELVN) stock. It includes analyst price targets, historical price performance, volatility, market capitalization, upcoming earnings dates, and past financial results like EPS and revenue

Tone
Positive 70/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
TradingView
Sahm Direct company coverage

22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here

Enliven Therapeutics (ELVN) is currently valued at US$2.9 billion with shares at US$49.12, showing strong recent performance. Despite being loss-making and having a value score of 2, its Price-to-Book ratio of 6.6x is below its peer average but significantly above the broader US

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 10:10
Source
Sahm
Stock Titan Direct company coverage

OrbiMed funds trim Enliven Therapeutics (NASDAQ: ELVN) stake with 860K-share sale

OrbiMed-affiliated entities have reduced their stake in Enliven Therapeutics (NASDAQ: ELVN) by selling 860,123 shares on June 22, 2026, at prices ranging from $45 to $45.38 per share. Despite this sale, the funds still retain significant indirect holdings, with one fund holding o

Tone
Negative 31/100
Event
Deals and strategy
Published
25 Jun 2026 00:41
Source
Stock Titan
Investing.com Direct company coverage

OrbiMed entities sell $39 million in Enliven Therapeutics stock

OrbiMed entities, including OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital GP VII LLC, sold approximately $39 million worth of Enliven Therapeutics (NASDAQ:ELVN) common stock on June 22, 2026. The sale involved 860,123 shares at prices between $45.00 and $45.38

Tone
Negative 39/100
Event
Market update
Published
24 Jun 2026 23:41
Source
Investing.com
Stock Titan Direct company coverage

OrbiMed cuts Enliven Therapeutics (ELVN) holdings to 9.5% of shares

OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Enliven Therapeutics (ELVN) to 9.5% of outstanding shares, as reported in an Amendment No. 5 to their Schedule 13D filing. This reduction stems from open-market sales of Enliven shares by OPI VII,

Tone
Negative 38/100
Event
Market update
Published
24 Jun 2026 23:41
Source
Stock Titan
The Motley Fool Direct company coverage

Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?

Orbimed Advisors, a medical and biotech-focused hedge fund, recently sold 281,408 shares of Enliven Therapeutics Inc. (ELVN) for approximately $12.67 million, representing 3.67% of its indirect holdings. This transaction follows the biotech company's announcement of promising dat

Tone
Negative 37/100
Event
Market update
Published
24 Jun 2026 19:39
Source
The Motley Fool
TradingView Direct company coverage

ETFs Investing in Enliven Therapeutics, Inc. Stocks

This article lists various ETFs that invest in Enliven Therapeutics, Inc. (ELVN) stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, and assets under management for each fund. The ETFs primarily focus on small-cap, health

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 02:39
Source
TradingView
Investing.com Direct company coverage

Enliven Therapeutics stock hits 52-week high at 48.55 USD

Enliven Therapeutics Inc. has achieved a significant milestone, with its stock reaching a 52-week high of $48.55 and currently trading at $48.72, boasting a 198% year-to-date return. This strong performance is supported by recent successful public offerings totaling around $460 m

Tone
Positive 94/100
Event
Market update
Published
23 Jun 2026 21:10
Source
Investing.com
Investing.com Direct company coverage

Enliven Therapeutics CFO Hohl sells $263,577 in stock

Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of the company's common stock for $263,577 on June 17, 2026, executed under a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high, generating a 193% year-to-date return. Prior to t

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 08:10
Source
Investing.com
Stock Titan Direct company coverage

Enliven Therapeutics (ELVN) CFO sells 6,018 shares after option exercise

Enliven Therapeutics (ELVN) CFO Benjamin Hohl exercised stock options for 6,018 shares at $2.48 each and subsequently sold all 6,018 shares in open-market transactions on June 17, 2026, at weighted average prices between $42.79 and $44.75. These transactions were executed under a

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 08:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Enliven Therapeutics Inc For: 22 June By Investing.com

This article from Investing.com announces the filing of a Form 4 for Enliven Therapeutics Inc. on June 22. It is a brief, one-line report with a reference to Reuters. The article includes various market data, news headlines, and promotional content from Investing.com.

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:41
Source
Investing.com Canada
Investing.com Direct company coverage

Enliven Therapeutics CMO sells $219,016 in shares

Helen Louise Collins, CMO of Enliven Therapeutics (NASDAQ:ELVN), sold 4,900 shares for $219,016 on June 17, 2026, executed under a Rule 10b5-1 trading plan. These sales followed the exercise of stock options for 5,000 shares. The company's stock is trading near its 52-week high a

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:41
Source
Investing.com
Stock Titan Direct company coverage

Enliven Therapeutics (ELVN) CMO exercises 5,000 options and sells 5,000 shares

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised 5,000 stock options at $2.48 per share and subsequently sold 5,000 shares of common stock in three open-market transactions on June 17, 2026. The sales were conducted under a pre-arranged Rule 10b5-1 tra

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:41
Source
Stock Titan